Remove Medicine Remove Networking Remove Pharmaceutical research Remove Safety
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed. Andrea Pfeifer, PhD In 2003, Andrea Pfeifer co-founded AC Immune SA.

article thumbnail

The Dark Side of the Pharmaceutical Industry: Are Treatments Being Blocked for Profit?

Pharma Marketing Network

This involves paying researchers and scientists to publish articles or conduct studies that support the use of a particular drug, while suppressing or ignoring research that casts doubt on the drug’s safety or efficacy. Pharmaceutical research and development: what do we get for all that money?

article thumbnail

Dawn of a new indication: how to study drugs for agingĀ 

Pharmaceutical Technology

Nir Barzilai, the scientific director for TAME and the director of the Institute for Aging Research at the Albert Einstein College of Medicine, New York, says projects like the TAME trial could be what regulators need to see to prove the validity of clinical trials in this area.

FDA 145